- Home
- WF vs MRNA Comparison
WF vs MRNA Comparison
Compare WF & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WF
- MRNA
- Stock Information
- Founded
- WF 1899
- MRNA 2010
- Country
- WF South Korea
- MRNA United States
- Employees
- WF N/A
- MRNA N/A
- Industry
- WF Commercial Banks
- MRNA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- WF Finance
- MRNA Health Care
- Exchange
- WF Nasdaq
- MRNA Nasdaq
- Market Cap
- WF 13.6B
- MRNA 10.9B
- IPO Year
- WF N/A
- MRNA 2018
- Fundamental
- Price
- WF $53.60
- MRNA $24.09
- Analyst Decision
- WF
- MRNA Hold
- Analyst Count
- WF 0
- MRNA 19
- Target Price
- WF N/A
- MRNA $43.50
- AVG Volume (30 Days)
- WF 38.0K
- MRNA 8.9M
- Earning Date
- WF 10-24-2025
- MRNA 08-01-2025
- Dividend Yield
- WF 3.90%
- MRNA N/A
- EPS Growth
- WF 6.29
- MRNA N/A
- EPS
- WF 2.73
- MRNA N/A
- Revenue
- WF $7,611,646,475.00
- MRNA $3,078,000,000.00
- Revenue This Year
- WF N/A
- MRNA N/A
- Revenue Next Year
- WF $2.30
- MRNA $10.17
- P/E Ratio
- WF $6.51
- MRNA N/A
- Revenue Growth
- WF N/A
- MRNA N/A
- 52 Week Low
- WF $29.44
- MRNA $23.15
- 52 Week High
- WF $57.97
- MRNA $79.96
- Technical
- Relative Strength Index (RSI)
- WF 49.78
- MRNA 33.51
- Support Level
- WF $53.00
- MRNA $26.01
- Resistance Level
- WF $54.42
- MRNA $25.64
- Average True Range (ATR)
- WF 0.75
- MRNA 1.12
- MACD
- WF -0.17
- MRNA -0.22
- Stochastic Oscillator
- WF 21.19
- MRNA 5.16
About WF Woori Financial Group Inc. (each representing three (3) shares of)
Woori Financial Group Inc is a banking and financial services holding company that offers a wide range of services, including corporate banking, consumer banking, credit card operations, investment banking, capital markets activities, international banking, asset management, and other businesses. The operating segments of the company include Banking, Credit card, Capital, Investment banking, and others.
About MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.